Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | TARS1 | P26639 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291611 | 1.00 | RXFP1 (0.54) | RXFP1TARS1ADORA1CA1CA2 | |
| SCHEMBL20508942 | 1.00 | RXFP1 (0.54) | RXFP1TARS1ADORA1CA1CA2 | |
| SCHEMBL12379253 | 1.00 | RXFP1 (0.54) | RXFP1TARS1ADORA1CA1CA2 | |
| SCHEMBL19302773 | 0.92 | RXFP1 (0.56) | RXFP1TARS1ADORA1CA1CA2 | |
| SCHEMBL6762689 | 0.88 | ADORA1 (0.50) | ADORA1 | |
| SCHEMBL21859151 | 0.88 | ADORA1 (0.50) | ADORA1 | |
| SCHEMBL21859282 | 0.88 | ADORA1 (0.50) | ADORA1 | |
| SCHEMBL30867101 | 0.88 | ADORA1 (0.50) | ADORA1 | |
| SCHEMBL22220143 | 0.88 | ADORA1 (0.50) | ADORA1 | |
| SCHEMBL13986326 | 0.86 | ADORA1 (0.51) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-22 | — | — | US | disclosed |
| US-20200268794-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200215111-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200157518-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157518-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | CD2, PBK, CD4 | RXFP1 3340/4885TARS1 3839/4885ADORA1 2064/4885 |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | RXFP1 3009/4885TARS1 3622/4885ADORA1 2149/4885 |
| US-20200268794-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | RXFP1 3009/4885TARS1 3622/4885ADORA1 2149/4885 |
| US-20200215111-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | CD2, PBK, CD4 | RXFP1 3340/4885TARS1 3839/4885ADORA1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.